Intrinsiqq
Pro-Dex Inc. logo

Pro-Dex Inc. Quality Score

PDEX

⊜ Compare
Quality86

Strong across all measured dimensions. No single area is pulling the score down meaningfully.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
90/100
17.4x

Under 20x, reasonable relative to earnings

Cash Flow Multiple
90/100
19.0x

Under 20x cash flow, well covered

Revenue Growth
100/100
14.6%

Above 10% CAGR, strong compounder

Cash Flow Growth
60/100
Just turned +

Recently turned FCF-positive, capex cycle finishing, CAGR not yet meaningful

Business Quality & Capital Allocation

Share Dilution
100/100
-8.8%

Shrinking >2%, active buybacks

Margin Trend
100/100
+4.3pp

Expanded 3+pp, strong improvement

Capital Structure
60/100
$10M

Net debt/FCF of 1.0x, manageable

2023
$4.00M
$18.0M
2024
$7.00M
$18.0M
2025
$7.00M
$22.0M
2026
$9.00M
$22.0M
TTM
$13.0M
$23.0M
CashDebt
Return on Capital
80/100
15.3%

15–20%, well above cost of capital

Customize WeightsPremiumUpgrade

Pro-Dex (PDEX) quality: score, margins and returns

Pro-Dex (PDEX) scores 86/100 on Intrinsiqq's quality score (a high-quality business), a weighted blend of 7 metrics each scored 0 to 100, on 16.8% operating margins and 15.3% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Pro-Dex (PDEX) a high-quality business?+

Pro-Dex scores 86 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which rates it a high-quality business on these measures. Recent figures include a 16.8% operating margin and a 15.3% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Pro-Dex's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from PDEX's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Pro-Dex scores well and where it falls behind.

What is Pro-Dex's return on invested capital (ROIC)?+

Pro-Dex earns about 15.3% on its invested capital, which is strong. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to PDEX's margins and growth on this scorecard to judge durability.

How profitable is Pro-Dex?+

Pro-Dex runs an operating margin of about 16.8% and a net margin of about 15.1%. Revenue has grown at roughly 15.3% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 28 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 30 Oct 2026. How this is calculated.

Fiscal year ends Jun. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Surgical & Medical Instruments & Apparatus · Pick stocks to compare with PDEX

CompareIntrinsic value
TELATela Bio Inc.
$0.87+8.72%30
SGHTSight Sciences, Inc.
$9.68+2.76%33
RCELAvita Medical Inc.
$16.32+6.46%30
IRMDIradimed Corp
$88.58+9.21%80
LUNGPulmonx Corporation
$2.83+4.04%30
DCTHDelcath Systems Inc.
$14.82+2.92%62
CARLCarlsmed, Inc.
$16.09+11.74%44
MHUAFMeihua International Medical Technologies Co., Ltd.
$6.30-8.16%59

Held by ETFs

PDEX is in 9 US ETFs. The largest of them, with PDEX's weight in each:

Spot a number that looks wrong? Check it in PDEX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PDEX

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.